Eplontersen,Inotersen
Ionis Pharmaceuticals,Akcea Therapeutics,Astrazeneca
[]
a phase 3 clinical trial showed the new treatment #eplontersen significantly reduced the disease-causing protein and halted progression of #hattr-polyneuropathy. sami khella of presented the results at #aanam.
News about biomedical research, patient care, and medical education at the University of Pennsylvania from the Penn Medicine Department of Communications.